1 / 78

New Insights into the Definitive Management of VTE

New Insights into the Definitive Management of VTE. Understanding the Burden of VTE. Population-Based Studies: High Incidence of VTE. VTE: An Important Problem Among Hospital Patients. Percentage of Patients at Risk for VTE by Country.

jescie-duncan
Télécharger la présentation

New Insights into the Definitive Management of VTE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Insights into the Definitive Management of VTE

  2. Understanding the Burden of VTE

  3. Population-Based Studies: High Incidence of VTE

  4. VTE: An Important Problem Among Hospital Patients

  5. Percentage of Patients at Risk for VTE by Country

  6. Percentage of At-Risk Patients Receiving Recommended Prophylaxis

  7. Pulmonary Embolism Carries a High Mortality Rate

  8. Poor Clinical Outcomes After VTE Treatment

  9. Recurrent VTE is a Common Complication

  10. Incidence of VTE recurrence

  11. VTE Recurrence With Continued vs Shorter VKA Treatment

  12. Incidence of Major Bleeding With Continued vs Shorter VKA Treatment

  13. Post-thrombotic Syndrome

  14. Patients With VTE are at Risk for Subsequent Development of Venous Ulcers

  15. Anticoagulant Control and PTS

  16. Chronic Thromboembolic Pulmonary Hypertension

  17. Cost Burden of VTE and Long-Term Complications

  18. Conclusion

  19. Anticoagulant Profiles: What You Need to Know

  20. Currently Available Anticoagulants

  21. Targets of “Classical” Anticoagulants: Heparin and VKAs

  22. Warfarin -- Narrow Therapeutic Window

  23. Challenges and Limitations of VKAs

  24. Risks of Stroke and Mortality Associated With Suboptimal Anticoagulation in AF Patients

  25. Anticoagulation Control and Prediction of Adverse Events in Patients With AF

  26. The SAMe-TT2R2 score

  27. Targets of NOACs

  28. Absorption and Metabolism of NOACs

  29. NOACs in Chronic Kidney Disease

  30. Renal Impairment in a “Real-Life” Cohort of Anticoagulated Patients With AF

  31. Anticoagulant Profiles: What You Need to Know

  32. At the Crossroads: Deciding Factors for Optimizing VTE Treatment

  33. Conventional 2-stage Treatment of VTE

  34. New Oral Anticoagulants

  35. Comparisons of Designs of Phase III Acute VTE Trials

  36. RE-COVER I and II:Efficacy and Safety Outcomes

  37. Extended VTE Treatment With Dabigatran

  38. EINSTEIN DVT and PE Trials:Efficacy and Safety Outcomes

  39. EINSTEIN Extension Study

  40. AMPLIFY

  41. Dabigatran, Rivaroxaban, or Apixaban for VTE Treatment

  42. What Have We Learned So Far?

  43. AMPLIFY EXTENSION Study

  44. What Do We Still Need to Know?

  45. Which VTE Patients Are Candidates for New Anticoagulants?

  46. Which VTE Patients Are Not Candidates for New Anticoagulants?

  47. Where is There Uncertainty for VTE Patients Using New Anticoagulants?

  48. Opportunities for New Oral Anticoagulants in VTE

  49. Challenges for New Oral Anticoagulants

More Related